Ipamorelin FAQ: Half-Life, Effects, Safety, and Regulatory Status
How to reconstitute CJC-1295 ipamorelin 5mg?
Reconstitution means dissolving a lyophilized (freeze-dried) peptide powder in bacteriostatic water for research handling; this site does not provide preparation protocols or volumes. Note that the popular CJC-1295 + ipamorelin combination has never been tested as a combination in any controlled trial — its support is single-agent pharmacology only, and no human dosing basis exists for it [3].
How long does ipamorelin stay in your system?
In the one human study, ipamorelin's terminal half-life was about 2 hours, with clearance 0.078 L/h/kg [2]. By the four-to-five-half-lives rule, the drug is largely cleared within roughly 8-10 hours. Detection in urine by anti-doping laboratories is a separate matter and can extend beyond the pharmacological effect [12]. Full detail is on the how long does ipamorelin stay in your system page.
How long does it take for ipamorelin to work?
The immediate action is fast: the growth-hormone pulse peaks about 40 minutes (0.67 hours) after a dose in the human pharmacokinetic study [2]. Community-reported effects such as deeper sleep are described over one to two weeks, but those are anecdotal, not clinical findings. See the how long does it take for ipamorelin to work page for both timelines.
What is the half-life of ipamorelin?
The terminal half-life is approximately 2 hours in healthy human volunteers, measured by intravenous population PK/PD modeling, alongside a clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg [2]. This is the single best-characterized human pharmacokinetic figure for the compound and the lead lens of this site.
Is ipamorelin available in an oral form?
Ipamorelin itself is not orally bioavailable. Engineered analogs derived from ipamorelin achieved only about 10-55% oral bioavailability in dogs, illustrating the structural difficulty of making this peptide class orally active [8]. The routes used in research are intravenous, subcutaneous, intranasal, and intraperitoneal — not oral [2].
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively activates the ghrelin / GHS-R1a receptor to release a pulse of growth hormone. Its founding characterization established it as the first highly GH-selective secretagogue — potent GH release without raising ACTH or cortisol [1]. It is a research chemical, not an approved drug.
What does ipamorelin do for you?
In studies, ipamorelin triggers a discrete growth-hormone pulse via the ghrelin receptor, without the cortisol rise older peptides cause [1]. Beyond that measured action, it has no proven human benefit: the only Phase 2 trial, for postoperative ileus, missed its primary endpoint [3]. Community-reported effects exist but are anecdotal — see the effects page.
What is ipamorelin peptide?
Ipamorelin peptide is the same compound — a five-amino-acid (pentapeptide) growth hormone secretagogue. 'Peptide' simply notes that it is a short chain of amino acids. It mimics the body's hunger hormone ghrelin at the GHS-R1a receptor to release growth hormone, and is distinguished by its selectivity for GH over cortisol and prolactin [1].
What are the risks of ipamorelin?
The documented risks are mostly gaps: no Phase 3 trial, no long-term human safety data, and a failed Phase 2 efficacy trial [3]. Mechanistically, GH-axis stimulation raises theoretical concerns around IGF-1 and proliferation, and a class-level rat study of a related agonist found heart-muscle damage over 28 days [6]. Cited cautions are on the effects page.
Does ipamorelin reduce belly fat?
No human trial has shown ipamorelin reduces belly fat. The relevant animal data are indirect: in a 2024 ferret study, ipamorelin inhibited chemotherapy-induced weight loss by about 24% [9], and community reports describe gradual leaning over weeks — but those are anecdotal and confounded by diet and training [3]. There is no controlled-trial evidence for fat reduction in humans.
What are the downsides of ipamorelin?
The central downside is the evidence gap: its only Phase 2 trial failed its primary endpoint and it has never been approved [3]. Practical downsides reported by users include facial flushing, appetite increase, water retention, and injection-site irritation — all anecdotal [9]. Supply is also a concern, as research-grade material from unregulated sources has unverified purity.
Why is ipamorelin being discontinued?
Ipamorelin was never an approved product to discontinue. Its clinical development effectively ended when the Phase 2 postoperative-ileus trial missed its primary endpoint (time to first tolerated meal 25.3 vs 32.6 hours, p=0.15) [3]. Separately, in 2024 the FDA removed ipamorelin acetate from Category 2 of the 503A bulk-substances list, tightening compounding-pharmacy access [3].
What does CJC-1295 and ipamorelin do?
In combination, CJC-1295 (a GHRH analog) and ipamorelin (a ghrelin-receptor peptide) are intended to release growth hormone through two complementary pathways at once [1]. The rationale is mechanistically sound, but there are no controlled trials of the combination for any outcome — its support is the separate single-agent pharmacology of each [3].
Does ipamorelin increase IGF-1?
Not consistently in short studies. In the rat bone-growth study, ipamorelin raised bone-growth rate with no measurable change in total IGF-1, suggesting a partly local GH effect [4]. In sustained protocols, GH-axis stimulation can raise hepatic IGF-1, but this is context-dependent and was not elevated in the short rodent windows tested [1].
How does CJC-1295 ipamorelin work?
CJC-1295 acts on the GHRH receptor while ipamorelin acts on the separate ghrelin/GHS-R1a receptor; both converge on pituitary cells to release growth hormone, so engaging both pathways can in principle produce a larger pulse than either alone [1]. This is a mechanistic rationale, not a trial-proven combination effect [3].
How much CJC-1295 ipamorelin should I take?
This site does not provide human dosing. No approved dose exists, and the CJC-1295 + ipamorelin combination has never been studied in a controlled human trial, so any circulating 'stack' protocol has no peer-reviewed basis [3]. The studied human ipamorelin doses were all intravenous and clinic-administered [2].
Does CJC-1295 ipamorelin work?
There is no controlled-trial evidence that the CJC-1295 + ipamorelin combination 'works' for anti-aging, fat loss, or muscle gain — those claims rest on mechanism and single-agent pharmacology [3]. Each peptide releases GH in studies [1], but the combination as marketed has not been tested against any clinical outcome in humans.
Does ipamorelin make you hungry?
It can, by mechanism. Ipamorelin acts on the ghrelin receptor — the same receptor the body's natural hunger hormone uses — so increased appetite is an expected class effect, and some users report a hunger uptick after dosing [7]. Community accounts describe it as milder than with GHRP-6, but appetite increase is among the more mechanistically predictable effects.
Will I gain weight on ipamorelin?
There is no human-trial answer. In mice, ipamorelin showed GH-independent increases in fat mass and leptin after two weeks [7], and its ghrelin-receptor mechanism can raise appetite — so weight gain is plausible by mechanism. But the only human trial measured bowel recovery, not body weight [3]. Community reports vary and are anecdotal.
Does ipamorelin increase appetite?
By its mechanism, yes — ghrelin-receptor (GHS-R1a) agonists activate hypothalamic appetite centers and induce feeding in animal studies [7]. Users commonly report increased hunger in the hours after a dose, generally described as milder than with the older peptide GHRP-6 [7]. This is one of the more predictable effects given how the compound works.
What does ipamorelin peptide do?
Ipamorelin peptide selectively activates the ghrelin/GHS-R1a receptor on the pituitary to release a single growth-hormone pulse, without the cortisol or prolactin rise caused by less selective peptides [1]. That measured hormonal action is its defining function; proven human therapeutic benefit does not exist, as the one Phase 2 trial failed [3].
Does ipamorelin cause water retention?
Some users report mild, transient water retention and puffiness in the first few weeks, generally described as milder than with older GHRP compounds — but this is anecdotal, not from a controlled trial [3]. Mechanistically, GH excess is associated with sodium and fluid retention, which gives the reports a plausible basis without confirming them.